Kabiven

Amino acid solution for parenteral nutrition, the active ingredient in Kabiven, is an amino acid solution presented as a solution for injection for intravenous use. It provides essential and non‑essential amino acids to support protein synthesis and nitrogen balance in patients receiving parenteral nutrition.

GNH USA supplies Kabiven as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Kabiven is used in parenteral nutrition to provide amino acids for patients who cannot receive enteral feeding.

Parenteral nutrition for patients unable to receive enteral feeding: Supplies essential amino acids to maintain nitrogen balance. Critically ill patients requiring protein synthesis support: Enhances tissue repair and recovery. Postoperative nutritional support: Assists in wound healing and metabolic stability.

Kabiven may be associated with a range of infusion‑related reactions.

Common Side Effects: - Hyperglycemia: Elevated blood glucose levels during infusion. - Electrolyte imbalance: Shifts in serum potassium, sodium, or calcium. - Phlebitis at infusion site: Local irritation or inflammation. - Mild nausea: Transient gastrointestinal discomfort.

Serious or Rare Side Effects: - Anaphylactic reaction: Severe allergic response requiring immediate intervention. - Metabolic acidosis: Accumulation of acidic metabolites. - Severe hyperosmolarity: High osmolar load leading to fluid shifts. - Renal impairment: Deterioration of kidney function in susceptible patients.

When using Kabiven, clinicians should observe several safety measures.

Renal function: Assess creatinine clearance before initiation. Electrolyte monitoring: Check serum levels regularly during therapy. Fluid balance: Adjust infusion rate to avoid overload. Metabolic disorders: Monitor for hyperammonemia or acidosis. Compatibility: Do not mix with incompatible solutions. Store at 2-8°C: Keep refrigerated, protect from light, do not freeze or shake.

Kabiven can interact with other intravenous agents and systemic therapies.

Major Interactions (Avoid): - Calcium‑containing solutions: May precipitate amino acids. - High‑dose glucose infusions: Increase risk of hyperglycemia.

Moderate Interactions (Monitor Closely): - Loop diuretics: May affect electrolyte balance. - Corticosteroids: Can increase protein catabolism. - Insulin therapy: May require dose adjustment.